Augustine Asset Management Inc. Boosts Stock Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Augustine Asset Management Inc. raised its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 392.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 249,744 shares of the company’s stock after acquiring an additional 199,044 shares during the quarter. Dr. Reddy’s Laboratories makes up 1.0% of Augustine Asset Management Inc.’s holdings, making the stock its 18th largest holding. Augustine Asset Management Inc.’s holdings in Dr. Reddy’s Laboratories were worth $3,943,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its holdings in shares of Dr. Reddy’s Laboratories by 453.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the period. State Street Corp lifted its holdings in shares of Dr. Reddy’s Laboratories by 1.9% in the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock worth $72,292,000 after buying an additional 16,641 shares during the period. Fisher Asset Management LLC grew its position in shares of Dr. Reddy’s Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after buying an additional 183,146 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Dr. Reddy’s Laboratories by 30.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock worth $32,530,000 after buying an additional 96,339 shares in the last quarter. Finally, Artemis Investment Management LLP raised its holdings in shares of Dr. Reddy’s Laboratories by 398.3% in the fourth quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock valued at $4,666,000 after acquiring an additional 236,224 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $13.82 on Wednesday. The company has a market capitalization of $11.53 billion, a PE ratio of 22.00 and a beta of 0.50. The company has a 50-day simple moving average of $14.76 and a two-hundred day simple moving average of $15.34. Dr. Reddy’s Laboratories Limited has a one year low of $13.36 and a one year high of $16.89. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on RDY shares. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Barclays dropped their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Finally, StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.